Vivos Unveils $3.6M Cost-Cut Plan, Targets Cash Flow Positive by Early 2027
VVOS sits 19% above its 52-week low of $0.13 on light trading volume (0.1× avg).
Summary
Vivos Therapeutics announced a restructuring plan to cut $3.6 million in annual overhead starting Q4 2026, alongside multiple revenue growth initiatives. The company says Las Vegas referrals tripled from June through late September, EEG diagnostics could reach a $1.5M-$3.0M annualized run rate in Q4, and Remote Patient Monitoring may add up to $3.5M annualized by Q1 2027. Payer contract renegotiations are expected to contribute $2.4M-$5.6M in early 2027. Management believes these moves put the company on track to be cash flow positive by late 2026 or early 2027 and profitable in 2027. This follows a Q2 2026 10-Q showing a $5.5M loss, $1.8M cash, and a going concern warning, so the cost cuts and revenue targets are critical to survival. The stock trades at $0.1545 with a market cap of $4.5M, making this a high-risk, high-reward situation. Watch for Q4 2026 results to confirm whether the savings and revenue ramp materialize as projected.
At the time of this announcement, VVOS was trading at $0.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.13 to $3.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.